soft tissue sarcoma epidemiology forecast

Soft Tissue Sarcoma (STS) Insights and Trends

• STS is a rare and heterogeneous group of malignant tumors arising from mesenchymal tissues such as muscle, fat, nerves, blood vessels, and connective tissues, often characterized by aggressive progression, high recurrence risk, and metastatic potential, leading to substantial morbidity and negatively impacting survival outcomes and quality of life.
• As per DelveInsight research, the 7MM reported approximately 40,000 incident cases of STS in 2025, with the patient pool expected to increase through 2036 due to improved diagnosis, aging populations, and longer survival outcomes.
• According to DelveInsight’s analysis, the US accounted for the highest number of STS incident cases in 2025, exceeding 13,500 cases, highlighting the substantial clinical burden in the region.
• STS epidemiology is characterized by small, dispersed patient populations and significant subtype heterogeneity, creating challenges in accurately assessing incidence, prevalence, and subtype-specific disease burden across populations
• Beyond systemic progression, STS imposes significant morbidity through local tumor effects such as pain, organ compression, and functional impairment, particularly in retroperitoneal and extremity disease. These effects often drive clinical deterioration independent of metastatic spread.

Soft Tissue Sarcoma (STS) Epidemiology Forecast

DelveInsight’s “Soft Tissue Sarcoma (STS) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of STS historical and forecasted epidemiology trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Soft Tissue Sarcoma (STS) epidemiology report provides a comprehensive analysis of incident cases, capturing the number of patients across the 7MM. It includes detailed segmentation by age group, histological subtype, disease stage, and regional distribution. The report evaluates historical and forecasted incidence trends (2022–2036), highlighting variations in disease occurrence, diagnosis patterns, and subtype-specific burden, while offering insights into the evolving population of newly diagnosed STS cases.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, and Spain and the United Kingdom
• Asia-Pacific: Japan

Soft Tissue Sarcoma (STS) Understanding

Soft Tissue Sarcoma (STS) Overview and Diagnosis

STS is a heterogeneous group of malignant tumors arising from mesenchymal tissues, including muscle, fat, fibrous tissue, blood vessels, and peripheral nerves. The disease can occur in various anatomical locations, most commonly in the extremities, trunk, retroperitoneum, and head and neck regions. STS encompasses multiple histological subtypes with diverse molecular characteristics and clinical behavior, ranging from indolent localized tumors to highly aggressive metastatic disease. The pathophysiology of STS involves complex genetic and molecular alterations that promote abnormal cellular proliferation, angiogenesis, invasion, and metastatic spread. Clinical manifestations commonly include painless enlarging soft tissue masses, localized pain, swelling, or functional impairment depending on tumor size and location. STS can broadly be categorized based on histological subtype, tumor grade, and extent of disease progression, all of which significantly influence prognosis, treatment strategies, and clinical outcomes.

The diagnostic evaluation of STS begins with a comprehensive clinical assessment focused on identifying suspicious soft tissue masses and differentiating benign from malignant lesions. Diagnostic workup typically includes detailed physical examination along with imaging modalities such as MRI, CT, and ultrasound to evaluate tumor size, anatomical location, local invasion, and metastatic spread. Definitive diagnosis relies on tissue biopsy and histopathological evaluation, while molecular and genetic testing may further support subtype classification and characterization of underlying biological alterations. Because STS comprises multiple histological subtypes with diverse clinical behavior, accurate diagnosis requires careful integration of radiological, pathological, and molecular findings to understand disease extent and biological complexity.

Further details related to country-based variations are provided in the report…

Soft Tissue Sarcoma (STS) Epidemiology

Key Findings from STS Epidemiological Analysis and Forecast

• In the US, localized STS represented the largest proportion of incident cases, with approximately 8,400 cases reported in 2025. Meanwhile, an estimated 2,500 cases were diagnosed at the distant stage, underscoring the persistent burden of advanced and metastatic disease.
• In 2025, Germany reported the highest share of type-specific STS cases in sarcoma NOS, accounting for approximately 1,500 cases, followed by liposarcoma with 1,050 cases, reflecting the heterogeneous histological landscape of STS in the country.
• In 2025, gender-specific STS cases in Spain were higher among males, with approximately 1,200 cases, compared with 1,050 cases among females, indicating a modest male predominance in the disease burden.
• In 2025, age-specific STS cases in Japan were highest among patients aged =65 years, with approximately 2,700 cases, followed by 45–64 years (~1,700), 20–44 years (~1,000), and <20 years (~400), indicating a higher disease burden in older populations.

Industry Experts and Physician Views for Soft Tissue Sarcoma (STS)

To keep up with STS epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the STS epidemiology, incidence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in STS, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Anderson Cancer Center, University Hospital Essen, La Timone University Hospital, etc. were contacted.

Their opinion helps understand and validate STS epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in STS.

Scope of the Report

• The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of STS, including its causes, risk factors, and factors influencing disease occurrence.
• Comprehensive insights are provided into incidence trends and forecasts, along with the future growth potential of incidence rates and evolving patterns of disease detection across the 7MM.
• Additionally, the report includes detailed segmentation of incident cases by age and gender offering a granular view of the epidemiological landscape.
• A thorough assessment of historical and forecasted incidence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.
• The report provides strategic insights by highlighting trends in incidence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the STS disease burden.

Report Insights

• STS incidence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.
• Report Key Strengths
• Epidemiology-based (EPI - based) bottom-up forecasting
• Artificial Intelligence (AI) - enabled epidemiology research report
• 11-year forecast
• STS epidemiological outlook (North America, Europe, Asia-Pacific)
• STS Burden trends (by geography)

Report Assessment

• Soft Tissue Sarcoma (STS) Diagnostic Trends.
• Soft Tissue Sarcoma (STS) Epidemiological Gaps.
• Soft Tissue Sarcoma (STS) Development Trends.
• Soft Tissue Sarcoma (STS) Emerging Research Focus.
• Soft Tissue Sarcoma (STS) Disease Burden Attractiveness.
• Soft Tissue Sarcoma (STS) Qualitative Epidemiological Insights.

FAQs

• What was the STS incident patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
• What are the anticipated variations in incidence and diagnosis rates across different geographies?
• What will be the future diagnosis and epidemiological trends of STS?
• What are the disease risks, burden, and key epidemiological gaps in STS? What are the growth opportunities based on the patient population across the 7MM?
• How will changes in incidence and diagnosis impact the overall epidemiological landscape?
• What are the current diagnosis practices and epidemiology trends of STS in the US, EU4, UK, and Japan?

Reasons to Buy

• The report will help in developing strategies by understanding the latest trends and changing epidemiology of STS.
• Bottom-up forecasting builds from the incident patient population, delivering a robust, data-driven epidemiological approach.
• Insights on patient burden/incidence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
• Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
• Identifying key trends in disease incidence will help anticipate shifts in the epidemiological landscape.
• Detailed analysis and segmentation of incident cases to provide visibility around high-burden patient groups.
• To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
• Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
• This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.